In the US, approximately 35 000 new cases of human papillomavirus (HPV)–associated cancers are diagnosed each year, including cervical, head and neck, anal, vulvovaginal, and penile cancers.
1 The incidence of HPV-associated head and neck cancers has been steadily increasing in North America and Europe
2,3 owing primarily to oropharyngeal squamous cell cancers, 75% of which are now HPV positive in the US.
4 Human papillomavirus status is a prognostic biomarker for oropharyngeal squamous cell carcinoma (OPSCC),
5 and National Comprehensive Cancer Network guidelines
6 recommend the use of HPV status to determine American Joint Committee on Cancer staging because HPV-positive OPSCC is now considered a distinct entity from HPV-negative OPSCC.
6,7 Whether HPV is a survival-favorable factor in cancer sites outside the oropharynx remains controversial; testing of nonoropharyngeal head and neck squamous cell carcinoma (non-OP HNSCC) tumors for HPV tumor status is currently not recommended by the National Comprehensive Cancer Network,
6 College of American Pathologists,
8 or American Society of Clinical Oncology.
9